Expanding our knowledge of dry AMD

Article

Professor Scott Cousins explains how we can use our knowledge of drusen formation to find new ways to combat dry age-related macular degeneration.

Key Points

Drusen development: the four theories

Currently, there are four key theories for explaining drusen formation. These are:

The role of inflammation

Our understanding of the disease has evolved rapidly in recent years. "I think that the greatest breakthrough in understanding the pathogenesis of drusen that we have had in the last five to seven years is this idea that inflammation, in various forms, is a major contributor to the disease; that the innate immune system plays a major role," asserted Professor Cousins. "In the last three years, there has been a lot of data published that show that the genetic impetus of AMD is found among the complement inhibitors in the complement system; specifically, Complement Factor H is the most important susceptibility gene.

"My laboratory, among others, has also looked at the role of one of the circulating white cells: the monocyte. We already know that its tissue equivalent, the macrophage, has a major role to play in wet AMD, but we're now learning it plays a role in dry AMD as well, and so we're exploring what this may mean for the development of the disease," Professor Cousins explained.

"The most recent breakthrough in our understanding was published in a New England Journal of Medicine article,"1 Professor Cousins continued. As previously reported by Ophthalmology Times Europe,2 this study examined the role of a mutation of the toll-like receptor 3 (TLR3) gene. TLR3 is a protein that alerts the immune system to infections, and a mutated form of the TLR3 gene, expressing leucine instead of phenylalanine, was shown to be protective against geographic atrophy, most likely by suppressing the death of RPE cells.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Related Content
© 2025 MJH Life Sciences

All rights reserved.